| |
[摘要]：Secukinumab (AIN-457) is a fully human monoclonal antibody that neutralizes IL-17, thus affecting the immune response driven by Th17 lymphocytes. The Th17 response has been described to contribute to the inflammatory reaction seen in multiple immune-mediated diseases. Moreover, studies in animal models of autoimmune disease have proven the biological effects of the blockade of IL-17. Mostly, a decrease in the clinical signs and progression of certain immune-mediated diseases was noted. Recently, the results of the use of secukinumab in patients with psoriasis, rheumatoid arthritis, noninfectious uveitis and ankylosing spondylitis have been encouraging. Anti-IL-17 therapy may therefore offer a new therapeutic strategy for patients with immune-mediated diseases. |
|
